Drug Database
YY

YY-3110 (YY 3110 / YY3110)

✓ Approved

YuYu Pharma · Small Molecule · Small Molecule

What is YY-3110?

YY-3110 is a small molecule developed by YuYu Pharma. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesYY 3110, YY3110
CompanyYuYu Pharma
Drug ClassSmall Molecule
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, YuYu Pharma

Therapeutic Indications

YY-3110 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersThrombosis✓ Approved

Related Research Articles

PubMedMicroorganisms2026-08-27

Contrasting the Microbial Communities in Rhizosphere and Bulk Soils Across Different Eucommia ulmoides Planting Sites and Their Soil Chemical Driving Mechanisms.

Liu Panfeng P, Wang Huaxiang H, Lin Furong F, Du Hongyan H et al.

Soil multifunctionality (SMF) is a core indicator of plantation soil ecological function, and microbial diversity plays a vital role in sustaining it. However, cross-site rhizosphere and bulk SMF disparities and their microbial driving mechanisms remain unclear in Eucommia ulmoides plantations. Here, we collected rhizosphere and bulk soils from three typical sites (Mengzhou, MZ; Liangyuan, LY; and Yuanyang, YY). Soil chemical properties, extracellular enzymes, microbial alpha diversity, community composition and cross-kingdom network topology were measured. Correlation heatmaps, random forest, Redundancy analysis (RDA) and Partial least path modeling (PLS-PM) were adopted to quantify SMF predictors and regulatory pathways. Rhizosphere soils possessed significantly higher alkaline hydrolyzable nitrogen (AN), available phosphorus (AP) and available potassium (AK) than bulk soils at all sites. LY rhizosphere showed the greatest soil organic carbon (SOC), total potassium (TK), available nutrients and enzyme activities, while YY had higher total nitrogen (TN) and AP, yet the lowest enzyme levels. Rhizosphere bacterial and fungal alpha diversity was consistently higher across locations. SMF varied distinctly by site and compartment: LY had substantially higher SMF than MZ and YY in both rhizosphere and bulk soils, with rhizosphere SMF being consistently greater than bulk values across all sites. The PLS-PM (GOF = 0.70) indicated that soil chemical properties regulated SMF via dual pathways: they directly promoted microbial co-occurrence networks and indirectly modified network structure by altering fungal diversity, while suppressing bacterial diversity. Total effect analysis identified soil chemical properties and microbial co-occurrence networks as the core drivers of SMF variation. This work clarifies that rhizosphere effects and soil chemical properties jointly drive SMF by regulating microbial diversity and co-occurrence networks, offering theoretical guidance for sustainable soil management in E. ulmoides plantations.

PMID 42655197
Read full article →
PubMedJAMA health forum2026-08-21

Health Care Workforce Immigration to the UK After Its European Union Membership Referendum.

Ramesh Tarun T, Leary Alison A, Zhang Fang F, Yu Hao H

The UK relies heavily on internationally trained physicians and nurses. The 2016 UK European Union (EU) membership referendum (Brexit referendum) introduced uncertainty regarding future migration policy, with unclear implications for health care workforce supply and National Health Service (NHS) staffing. To evaluate changes in immigration of internationally trained physicians and nurses to the UK after the Brexit referendum and to assess associated changes in NHS vacancies. A controlled interrupted time-series study was conducted to assess changes in physician and nurse immigration to the UK after the 2016 Brexit referendum, using annual data for 2008 through 2019 from the Organization for Economic Cooperation and Development (OECD) with 32 high-income OECD countries as the control group; an interrupted time-series study was undertaken to estimate changes in NHS England vacancies due to the Brexit referendum, using monthly vacancy data from April 2015 to December 2019. Data were analyzed from January 2024 to June 2025. 2016 Brexit referendum. Annual inflow of EU-origin, non-EU-origin, and total physicians and nurses to the UK; monthly NHS England physician and nursing vacancies. The analysis included 418 962 physicians and 358 122 nurses who emigrated to an OECD country from 2008 to 2019. In 2016, the Brexit referendum was associated with immediate reductions of 825 EU physicians (95% CI, -983 to -668) and 2771 EU nurses (95% CI, -2952 to -2590) relative to prereferendum trends. Non-EU immigration also fell in 2016 (-416 physicians [95% CI, -746 to -83]; -2912 nurses [95% CI, -3463 to -2362]) but increased significantly thereafter from 2017 to 2019 (added 3110 physicians per year [95% CI, 2745 to 3474] and 1437 nurses [95% CI, 1036 to 1838]). Overall, total physician inflow rose, while total nurse inflow declined. NHS England physician vacancies increased by 383 posts (95% CI, 88 to 679) immediately after the referendum; nursing vacancies showed no significant changes. In this cross-sectional study, the Brexit referendum's policy uncertainty produced a sustained decline in EU-origin health care worker immigration, partially offset by recruitment from non-EU countries. This substitution did not prevent increases in physician vacancies and persistent nursing shortfalls, underscoring the sensitivity of health workforce supply to migration policy. Policymakers considering similar restrictions should account for anticipatory effects, substitution dynamics, and potential consequences for global health equity.

PMID 42627655
Read full article →
PubMedTransboundary and emerging diseases2026-08-21

Highly Virulent Getah Virus Subgroup GIII-c Emerging in Pigs in China.

Xiang Zhaoying Z, Wang Xingchen X, Huang Yuchen Y, Gao Xinyu X et al.

Getah virus (GETV) is an emerging mosquito-borne zoonotic alphavirus that poses a threat to multiple animal species, particularly pigs, and carries significant public health implications. Nevertheless, the molecular evolution and pathogenicity of circulating GETV strains in China remain incompletely defined. In this study, three GETV strains were isolated from diseased piglets during concurrent outbreaks on three geographically distinct commercial pig farms in China in August 2025. The isolates shared 99.67%-99.91% genomic nucleotide (nt) identity and were phylogenetically classified into subgroup GⅢ-c. Amino acid sequence alignment against 136 reference strains from the GenBank database identified four substitutions in Nsp1 and Nsp3 that were absent from all reference strains, along with six conserved residues largely concentrated in a distinct subclade formed by the three isolates and five related reference strains. Pathogenicity evaluation using a representative isolate (GETV-YY/2025) in 7-day-old piglets revealed that the infected animals developed severe clinical signs, including fever, diarrhea, ataxia, and hindlimb paralysis, with a high mortality rate of 77.8% (7/9). The strain exhibited broad tissue tropism, with high viral loads detected in pharyngeal and rectal swabs, serum, and multiple visceral organs as early as 1 day postinoculation, accompanied by obvious cerebral vascular congestion and pulmonary hemorrhage. Notably, efficient contact transmission to sentinel piglets was observed, resulting in one fatality among the three contact animals (33.3%). Collectively, these findings characterize the emergence of a highly virulent GETV subgroup GⅢ-c circulating in Chinese pig populations, highlighting its capacity for efficient contact transmission and severe pathogenesis in neonatal pigs. This study provides critical insights into the evolutionary dynamics of GETV and informs the urgent development of prevention and control strategies against this re-emerging veterinary pathogen.

PMID 42626796
Read full article →
PubMedJAMA oncology2026-08-20

Racial and Ethnic Disparities in US Colorectal Cancer Mortality by County, Sex, and Age.

GBD US Health Disparities Collaborators, Strassle Paula D PD, Alvarez Christian S CS, Dwyer-Lindgren Laura L et al.

In the past 2 decades, substantial declines in national colorectal cancer (CRC) mortality rates have been observed in the US; however, it is unclear whether these improvements have happened ubiquitously across geography, race and ethnicity, sex, and age group. To assess variation in CRC mortality rates and changes over time, across county, race and ethnicity, sex, and age group (<45 years and ≥45 years). This US population-based cross-sectional study used validated small-area estimation models to estimate county-level CRC mortality rates by race and ethnicity, sex, and age group from 2000 to 2019. Data analysis was completed in May 2023. Estimates were stratified by county, race and ethnicity (American Indian or Alaska Native, Asian or Pacific Islander, Black, Hispanic or Latino, and White), sex (female and male), and age group (<45 years and ≥45 years) as reported on death certificates. The outcome of interest was CRC mortality rates per 100 000 individuals. Estimates were corrected for race and ethnicity misclassification on death certificates and age standardized. Among 3110 counties or combined county units with data from 2000 to 2019 (mean annual population, 306 million), most counties saw declines in CRC mortality among adults aged 45 years or older, from 82.5 (95% uncertainty interval [UI], 81.7 to 83.2) to 54.4 (95% UI, 53.9 to 54.9) deaths per 100 000 population among males and from 58.9 (95% UI, 58.4 to 59.3) to 39.7 (95% UI, 39.4 to 40.0) per 100 000 deaths among females 45 years or older. However, in 2019, considerable county-level variation, including within states, was observed. The largest county-level variation was observed among American Indian or Alaska Native males aged 45 years or older, ranging from 13.6 (95% UI, 8.2-20.8) to 213.5 (95% UI, 147.1-309.0) deaths per 100 000 population. Overall, 275 counties with unmasked estimates had CRC mortality rates of more than 100 deaths per 100 000 among at least 1 population (American Indian or Alaska Native females: 13 counties; American Indian or Alaska Native males: 92 counties; Black males: 182 counties; Hispanic or Latino males: 1 county; White males: 4 counties; all other populations: 0). CRC mortality rates among individuals aged younger than 45 years were stable or increased from 2000 to 2019. This cross-sectional study found significant improvements in CRC mortality in adults aged 45 years or older at the national level and across all racial and ethnic populations between 2000 and 2019. However, CRC mortality rates remain extremely high in some counties and populations. These findings can help inform targeted intervention strategies for communities at highest risk.

PMID 42623048
Read full article →
PubMedIndian pediatrics2026-08-19

Comparative Efficacy, Safety, and Cost of Different Intrapleural Fibrinolytic Agents for the Management of Empyema Thoracis in Children: A Systematic Review.

Malik Meenakshi M, Bhatt Sonia S, Gupta Sarika S, Kaur Hardeep H et al.

Pediatric empyema thoracis is a serious complication of bacterial pneumonia, and poses management challenges due to the absence of evidence-based guidelines on optimal treatment approaches. Intrapleural fibrinolytic agents are frequently used to enhance pleural drainage and avoid surgical intervention in pediatric empyema thoracis; however, the comparative efficacy, safety, and cost-effectiveness of different fibrinolytic agents remain uncertain. To systematically evaluate and compare the efficacy, safety, and cost of different intrapleural fibrinolytic agents in children with empyema thoracis, to develop evidence-based recommendations for informing clinical decision-making. A systematic search of PubMed, EMBASE, the Cochrane Library, Scopus, Web of Science, ProQuest, OpenGrey, and four clinical trial registries was done, from their inception. Studies were eligible for inclusion in the systematic review if they were randomized controlled trials (RCT) including children under 18 years old with empyema thoracis (defined by any standard definition), comparing different fibrinolytic agents such as streptokinase, urokinase, and tissue plasminogen activator. The main outcomes included treatment failure, need for surgery, serious adverse events, and short-term clinical outcomes. Other outcomes were length of hospital stay, symptom duration, and cost. A total of 3110 records was identified; after de-duplication, 2022 unique citations were screened. A three-step screening process identified no RCT meeting the eligibility criteria. The available studies had other study designs, or lacked pediatric data. Current evidence is insufficient to determine the most effective and safe fibrinolytic agent for pediatric empyema thoracis. There is an urgent need for well-designed, comparative pediatric trials to support evidence-based treatment guidelines.

PMID 42616246
Read full article →
PubMedFrontiers in endocrinology2026-08-15

Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy?

Burmeister Melissa A MA, Brown Skyler A SA, Greer Jakeem J JJ, Hoggatt Tyler J TJ et al.

Obesity is a chronic, multifactorial disease that has reached epidemic status. The glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) is a key therapeutic target to achieve weight loss and glycemic control in obesity and type 2 diabetes mellitus. Tirzepatide and retatrutide, the latest generation of GLP-1-incorporating multi-agonists, target multiple receptors in complementary systems to achieve marked and sustained weight loss. However, the associated gastrointestinal (GI) side effects (e.g., nausea, vomiting, diarrhea, abdominal pain) that often hinder patient compliance underscore a remaining need for therapies with better tolerability. GEP44, a novel, monomeric, chimeric peptide structurally based on native GLP-1, the GLP-1RA exendin-4 (Ex-4), and the gut-derived hormone peptide YY3-36 (PYY3-36), is an agonist at the GLP-1R and multiple neuropeptide Y (NPY) receptors. This review summarizes the design rationale for GEP44 and preclinical evidence supporting its beneficial metabolic effects and tolerability. Like GLP-1, PYY3-36 is associated with decreased food intake (FI), and co-administration of GLP-1RA and PYY3-36 elicits synergistic food intake (FI)- and body weight (BW)-reducing effects with similar or enhanced blood glucose (BG)-lowering effects. Studies examining the efficacy of GEP44 to promote weight loss and improve glucoregulation in lean vs. diet-induced obese rodents report that peripheral administration generally decreases BW, FI, and insulin resistance and increases EE at equivalent or greater magnitudes than those observed with single GLP-1RAs in a GLP-1R-dependent manner with improved GI tolerability. These beneficial actions reflect GEP44's potential to expand the mechanistic scope of anti-obesity medications.

PMID 42602523
Read full article →

+4513 more articles available with a free account

Sign up free to view all articles →

Ask about YY-3110